Press release
Knee Osteoarthritis Pipeline: Over 50 Innovators Pioneering Breakthrough Therapies | DelveInsight
Knee Osteoarthritis Pipeline
DelveInsight's "Knee Osteoarthritis Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the Knee Osteoarthritis market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical studies, regulatory progress, and key developments such as collaborations, mergers, funding, and designations.
For emerging Knee Osteoarthritis drugs, the Knee Osteoarthritis pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key Takeaways from the Knee Osteoarthritis Pipeline Report
• DelveInsight's Knee Osteoarthritis Pipeline analysis depicts a robust space with 50+ active players working to develop 60+ pipeline drugs for Knee Osteoarthritis treatment.
• The leading Knee Osteoarthritis companies include Bone Therapeutics, Moebius Medical, UnicoCell Biomed CO. LTD, Gwo Xi Stem Cell Applied Technology, Bioventus LLC, CAR-T (Shanghai) Biotechnology, Novartis, Personalized Stem Cells, Centrexion Therapeutics, Akan Biosciences, Samumed LLC, Purdue Pharma, Anika Therapeutics, Peptinov SAS, Flexion Therapeutics, Centrexion Therapeutics, Taiwan Liposome Company, Techfields Pharma, AstraZeneca, Ampio Pharmaceuticals, BioIntegrate, Sorrento Therapeutics, Swiss Medica XXI Century S.A., OrthoTrophix, R-Bio, Amzell, Eupraxia Pharmaceuticals, Meluha Life Sciences SDN BHD, Vivex Biomedical, Orient Europharma Co., Ltd., Paradigm Biopharmaceuticals, Abbvie, Galapagos NV, Regeneron Pharmaceuticals, Xalud Therapeutics, Yooyoung Pharmaceutical, Eupraxia Pharmaceuticals, Celltex Therapeutics Corporation, Eli Lilly and Company, Sclnow Biotechnology, Mestex AG, Mitsubishi Tanabe Pharma Corporation, Propella Therapeutics, PT. Prodia Stem Cell Indonesia, and others are evaluating their lead assets to improve the Knee Osteoarthritis treatment landscape.
• Key Knee Osteoarthritis pipeline therapies in various stages of development include Lorecivivint, EP-104IAR, LG00034053, JTA-004, X 0002, TTAX03, OLP 1002, PPV 06, Canakinumab, Elixcyte, GXCPC1, LNA043, CNTX-4975-05, Autologous adipose derived stromal vascular fraction therapeutic, Cingal, TLC599, and others.
• In February 2025, Aurora Pharmaceutical announced the availability of EquiCoxib, the FDA-approved generic equivalent of EQUIOXX (firocoxib), a non-steroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation associated with osteoarthritis.
• In February 2025, Zydus Lifesciences announced that it has received final approval from the USFDA to manufacture Ibuprofen and Famotidine tablets (800 mg/26.6 mg), branded as Duexis. This combination is used to relieve symptoms of rheumatoid arthritis and osteoarthritis and reduce the risk of upper gastrointestinal ulcers in patients using ibuprofen for these conditions.
• In November 2024, the US FDA completed a 30-day review of Paradigm Biopharmaceuticals' phase III pivotal clinical trial protocol for repurposed pentosan polysulfate sodium (ZILOSUL) to treat knee osteoarthritis (OA), clearing the way for the trial to begin in Q1 CY25.
Request a sample and discover the recent breakthroughs happening in the Knee Osteoarthritis pipeline landscape @ https://www.delveinsight.com/report-store/knee-osteoarthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Knee Osteoarthritis Overview
Osteoarthritis (OA) is the most common form of arthritis, often referred to as degenerative joint disease or "wear and tear" arthritis. It primarily affects the hands, hips, and knees, leading to cartilage breakdown and bone changes over time. This progressive condition causes pain, stiffness, swelling, and in severe cases, reduced mobility and disability. The knee joint, which connects the femur, tibia, fibula, and patella, relies on smooth cartilage for frictionless movement. When cartilage deteriorates, it cannot regenerate effectively, making OA a lasting and debilitating condition.
Find out more about Knee Osteoarthritis medication @ https://www.delveinsight.com/report-store/knee-osteoarthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Knee Osteoarthritis Treatment Analysis: Drug Profile
Lorecivivint: Biosplice Therapeutics
Lorecivivint (SM04690) is a small-molecule CLK/DYRK1A inhibitor targeting Wnt and inflammatory pathways. Preclinical studies suggest it has a dual mechanism of action-reducing inflammation, slowing cartilage degradation, and promoting cartilage generation. Currently, Lorecivivint is in Phase III clinical trials for knee osteoarthritis.
EP-104IAR: Eupraxia Pharmaceuticals Inc.
EP-104IAR is a long-acting corticosteroid therapy designed to provide extended pain relief for knee OA while minimizing systemic side effects. It encapsulates fluticasone propionate within a thin polymer membrane, allowing slow diffusion into the knee joint for up to six months. This approach aims to deliver sustained pain relief with an improved safety profile. Currently, EP-104IAR is in Phase II clinical trials for knee osteoarthritis.
Key Knee Osteoarthritis Therapies and Companies
• Lorecivivint: Biosplice Therapeutics
• EP-104IAR: Eupraxia Pharmaceuticals Inc
• LG00034053: LG Chem
• TLC599: Taiwan Liposome Company
• CNTX-4975: Centrexion Therapeutics
• HP-5000: Noven Pharmaceuticals
• Invossa (TG-C): Kolon TissueGene
Learn more about the novel and emerging Knee Osteoarthritis pipeline therapies @ https://www.delveinsight.com/report-store/knee-osteoarthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Knee Osteoarthritis Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.
By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
By Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
By Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Scope of the Knee Osteoarthritis Pipeline Report
• Coverage: Global
• Key Knee Osteoarthritis Companies: Bone Therapeutics, Moebius Medical, UnicoCell Biomed CO. LTD, Gwo Xi Stem Cell Applied Technology, Bioventus LLC, CAR-T (Shanghai) Biotechnology, Novartis, Personalized Stem Cells, Centrexion Therapeutics, Akan Biosciences, Samumed LLC, Purdue Pharma, Anika Therapeutics, Peptinov SAS, Flexion Therapeutics, Centrexion Therapeutics, Taiwan Liposome Company, Techfields Pharma, AstraZeneca, Ampio Pharmaceuticals, BioIntegrate, Sorrento Therapeutics, Swiss Medica XXI Century S.A., OrthoTrophix, R-Bio, Amzell, Eupraxia Pharmaceuticals, Meluha Life Sciences SDN BHD, Vivex Biomedical, Orient Europharma Co., Ltd., Paradigm Biopharmaceuticals, Abbvie, Galapagos NV, Regeneron Pharmaceuticals, Xalud Therapeutics, Yooyoung Pharmaceutical, Eupraxia Pharmaceuticals, Celltex Therapeutics Corporation, Eli Lilly and Company, Sclnow Biotechnology, Mestex AG, Mitsubishi Tanabe Pharma Corporation, Propella Therapeutics, PT. Prodia Stem Cell Indonesia, and others.
• Key Knee Osteoarthritis Pipeline Therapies: Lorecivivint, EP-104IAR, LG00034053, JTA-004, X 0002, TTAX03, OLP 1002, PPV 06, Canakinumab, Elixcyte, GXCPC1, LNA043, CNTX-4975-05, Autologous adipose derived stromal vascular fraction therapeutic, Cingal, TLC599, and others.
Dive deep into rich insights for drugs used for Knee Osteoarthritis treatment; visit @ https://www.delveinsight.com/report-store/knee-osteoarthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Table of Contents
1. Introduction
2. Executive Summary
3. Knee Osteoarthritis Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Knee Osteoarthritis Pipeline Therapeutics
6. Knee Osteoarthritis Pipeline: Late-Stage Products (Phase III)
7. Knee Osteoarthritis Pipeline: Late-Stage Products (Phase III)
8. Knee Osteoarthritis Pipeline: Mid-Stage Products (Phase II)
9. Knee Osteoarthritis Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix
Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Knee Osteoarthritis Pipeline: Over 50 Innovators Pioneering Breakthrough Therapies | DelveInsight here
News-ID: 3947790 • Views: …
More Releases from DelveInsight
Insulin Resistance Pipeline Insight 2025: Pipeline Drugs, Metabolic Pathway Modu …
DelveInsight's "Insulin Resistance - Pipeline Insight, 2025" explores over 10+ therapies in development for insulin resistance, a metabolic condition strongly linked to type 2 diabetes, obesity, and cardiovascular disease. Despite lifestyle modification and insulin-sensitizing drugs like metformin being mainstays of management, many patients continue to face poor glycemic control and associated complications, underscoring the need for more effective insulin resistance treatments.
The insulin resistance pipeline is broadening with next-generation therapies targeting…
Uveal Melanoma Pipeline Insight 2025: 30+ Pipeline Drugs, Targeted Therapies, an …
DelveInsight's "Uveal Melanoma - Pipeline Insight, 2025" explores over 30+ therapies in development for uveal melanoma, a rare and aggressive intraocular malignancy with high metastatic potential, most commonly to the liver. Despite surgery and radiotherapy being standards for localized disease, patients with metastatic uveal melanoma face limited systemic treatment options, creating significant unmet needs in the uveal melanoma treatment landscape.
The uveal melanoma pipeline is diversifying with next-generation targeted therapies, including…
Peptic Ulcers Pipeline Insight 2025: Emerging Therapies and Clinical Trials Shap …
DelveInsight's "Peptic Ulcers - Pipeline Insight, 2025" examines over 8+ therapies in development for peptic ulcer disease, a condition affecting millions worldwide with peptic ulcer disease symptoms such as abdominal pain, bloating, nausea, and gastrointestinal bleeding. Despite widespread use of existing peptic ulcer disease treatments, including proton pump inhibitors, H2 blockers, and antibiotics for H. pylori eradication, patients with recurrent or complicated peptic ulcers continue to face significant unmet needs,…
Vaso-Occlusive Crisis in Sickle Cell Disease: Emerging Therapies, Clinical Trial …
DelveInsight's "Vaso-Occlusive Crisis (VOC) Associated With Sickle Cell Disease - Pipeline Insight, 2025" provides an in-depth analysis of emerging therapies targeting vaso-occlusive crisis (VOC), a severe and recurring complication of sickle cell disease. Despite current standards of care, including hydroxyurea, patients continue to experience frequent vaso occlusive sickle cell crisis, underscoring the urgent need for effective interventions in sickle cell anemia vaso occlusive crisis treatment.
The VOC pipeline is diversifying with…
More Releases for Osteoarthritis
Osteoarthritis Market Massive Growth opportunity Ahead
Introduction
Osteoarthritis (OA), the most common form of arthritis, remains a significant global health burden, causing pain, mobility limitations, and reduced quality of life for millions. Driven by an aging population, lifestyle-related factors like obesity, and a growing focus on musculoskeletal health, the osteoarthritis market is witnessing notable transformation.
According to Exactitude Consultancy, the global osteoarthritis market was valued at USD 14 billion in 2024 and is projected to reach USD 22…
Rising Sports Injuries Fuel Growth In Osteoarthritis Therapeutics Market: The Dr …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Osteoarthritis Therapeutics Market Size Growth Forecast: What to Expect by 2025?
In recent times, the osteoarthritis therapeutics market has seen substantial growth. The market size was $8.17 billion in 2024 and is projected to rise to $8.87 billion in 2025, reflecting an annual compound growth rate (CAGR) of 8.6%.…
Osteoarthritis Treatment Market Trends and Forecast 2034
On March 20, 2025, Exactitude Consultancy., Ltd. announces the release of the report "Global Osteoarthritis Treatment Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2034". The report is a detailed and comprehensive analysis presented by region and country, type and application. As the market is constantly changing, the report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across…
Osteoarthritis Treatment Market
Introduction
Osteoarthritis (OA) is the most common form of arthritis, affecting millions worldwide. It is a degenerative joint disease that primarily impacts the cartilage and causes pain, stiffness, and reduced mobility. The growing prevalence of osteoarthritis, especially among the aging population, has created a significant demand for treatment options. The osteoarthritis treatment market includes various therapeutic approaches, such as medications, physical therapies, and surgical procedures, designed to manage the symptoms and…
Osteoarthritis Therapeutics Market - Finding Freedom from Osteoarthritis: Discov …
Newark, New Castle, USA: The "Osteoarthritis Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Osteoarthritis Therapeutics Market: https://www.growthplusreports.com/report/osteoarthritis-therapeutics-market/7779
This latest report researches the industry structure, sales, revenue,…
Osteoarthritis Therapeutics Market: Rising Obese and Geriatric Populations to In …
Industry is experiencing significant growth due to the rapid growth in the geriatric and obese population and the associated increase in the prevalence of osteoarthritis disease. Risk of adverse cardiovascular events associated with the use of NSAIDs in osteoarthritis treatment is likely to hamper the growth of the market.
What the Osteoarthritis Therapeutics Market Looks Like?
The osteoarthritis therapeutics market is projected to reach USD 10.1 billion by 2024 from USD 6.8…
